Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-1777 in moderate or severe atopic dermatitis
NCT04598269Phase 2Completed
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Sep 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lepzacitinib in atopic dermatitis (AD), sponsored by Aclaris Therapeutics, Inc.. Started Sep 2020; status: completed.
02
Drugs
lepzacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04598269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04598269.